CARESTAR – first patient recruited

We are happy and proud to support Acandis in the conduct of the CARESTAR study.

The CARESTAR Study aims to evaluate the clinical safety and efficacy of the CARESTO® heal Stent in routine clinical practice for patients with symptomatic non-stenotic carotid disease (SyNC), a condition in which carotid arteries are narrowed by less than 50% but still exhibit high-risk features that can lead to recurrent stroke.

This prospective, randomised, multicenter, international study investigates whether stenting with the CARESTO® Heal stent in addition to optimal medical therapy is superior to optimal medical therapy alone in preventing future strokes. CARESTAR has the potential to identify the best treatment strategy and optimise future therapeutic approaches. We’re excited to share that the first patient has been recruited — an important milestone for the entire team.

Looking forward to the next five years of partnership, innovation, and progress.

Learn more about the CARESTO® Heal stent